Suppr超能文献

多能干细胞在视网膜组织工程中的应用:现状与展望。

Pluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects.

机构信息

BioTime, Inc., 1010 Atlantic Avenue, Alameda, CA, 94501, USA.

出版信息

Stem Cell Rev Rep. 2018 Aug;14(4):463-483. doi: 10.1007/s12015-018-9802-4.

Abstract

The retina is a very fine and layered neural tissue, which vitally depends on the preservation of cells, structure, connectivity and vasculature to maintain vision. There is an urgent need to find technical and biological solutions to major challenges associated with functional replacement of retinal cells. The major unmet challenges include generating sufficient numbers of specific cell types, achieving functional integration of transplanted cells, especially photoreceptors, and surgical delivery of retinal cells or tissue without triggering immune responses, inflammation and/or remodeling. The advances of regenerative medicine enabled generation of three-dimensional tissues (organoids), partially recreating the anatomical structure, biological complexity and physiology of several tissues, which are important targets for stem cell replacement therapies. Derivation of retinal tissue in a dish creates new opportunities for cell replacement therapies of blindness and addresses the need to preserve retinal architecture to restore vision. Retinal cell therapies aimed at preserving and improving vision have achieved many improvements in the past ten years. Retinal organoid technologies provide a number of solutions to technical and biological challenges associated with functional replacement of retinal cells to achieve long-term vision restoration. Our review summarizes the progress in cell therapies of retina, with focus on human pluripotent stem cell-derived retinal tissue, and critically evaluates the potential of retinal organoid approaches to solve a major unmet clinical need-retinal repair and vision restoration in conditions caused by retinal degeneration and traumatic ocular injuries. We also analyze obstacles in commercialization of retinal organoid technology for clinical application.

摘要

视网膜是一种非常精细和分层的神经组织,对细胞、结构、连接和脉管系统的保存至关重要,以维持视力。目前迫切需要找到技术和生物学解决方案,以应对与视网膜细胞功能替代相关的主要挑战。主要的未满足需求包括生成足够数量的特定细胞类型、实现移植细胞的功能整合,特别是感光细胞,以及在不引发免疫反应、炎症和/或重塑的情况下进行视网膜细胞或组织的外科输送。再生医学的进步使三维组织(类器官)的生成成为可能,部分再现了几种组织的解剖结构、生物学复杂性和生理学,这些组织是干细胞替代治疗的重要靶点。在培养皿中获得视网膜组织为失明的细胞替代治疗创造了新的机会,并满足了保留视网膜结构以恢复视力的需求。在过去十年中,旨在保护和改善视力的视网膜细胞疗法取得了许多进展。视网膜类器官技术为解决与视网膜细胞功能替代相关的技术和生物学挑战提供了多种解决方案,以实现长期视力恢复。我们的综述总结了视网膜细胞疗法的进展,重点介绍了人类多能干细胞衍生的视网膜组织,并批判性地评估了视网膜类器官方法在解决主要未满足的临床需求方面的潜力,即在视网膜变性和创伤性眼部损伤引起的情况下进行视网膜修复和视力恢复。我们还分析了视网膜类器官技术在临床应用中的商业化障碍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405d/6013538/ced867690192/12015_2018_9802_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验